KIT and gastrointestinal stromal tumor: Moreover, FGF-2 has been shown as a potent factor capable of desensitizing GIST to IM treatment, thereby providing insights into the protective role of FGF-signaling in IM-treated GISTs and illustrating the novel molecular mechanism of IM resistance for GIST patients lacking secondary resistance mutations in KIT [18].